In Silico Identification of Small Molecules as Novel Coronavirus Protease Enzyme Inhibitors

Authors

  • Arkadeep Sarkar Research Scholar, BCDA College of Pharmacy and Technology, Hridaypur, Kolkata, West Bengal
  • Arghya Banik Research Scholar, BCDA College of Pharmacy and Technology, Hridaypur, Kolkata, West Bengal
  • Trambak Basak Research Scholar, BCDA College of Pharmacy and Technology, Hridaypur, Kolkata, West Bengal
  • Barun Dasgupta Research Scholar, BCDA College of Pharmacy and Technology, Hridaypur, Kolkata, West Bengal

Abstract

Abstract

The novel corona virus 2019 (COVID-19) is one of the global threats to the human civilization as it causes serious respiratory infection and multi-organ failure. Because of the absence of appropriate treatment protocol for 2019 novel corona virus, different methodologies are being tried in China, including drug repurposing. Recent discovery revealed the structure of novel corona virus main protease enzyme (Mpro) containing HIS41 and CYS145 amino acid residues present in catalytic domain, play crucial role in viral reproduction. Which facilities a promising approach to develop a new drug against COVID-19.  Therefore, successive inhibition of protease enzyme through a small molecular chemical analogue can be an effective approach to prevent the 2019 novel corona virus infection. In the present study, undertaking virtual screening approach-based screening of small molecule library was performed with the main protease enzyme protein of SARS CoV2. N-napthalen-1-yl methyl-2’-[3,5-dimethoxybenzamido]-2’deoxy-adenosine (DB03331)was identified as a small molecule showing satisfactory binding with this main protease enzyme. Physiochemical and pharmacokinetic assessment of proposed analogue was observed, which indicate, that the drug has suitable absorption, distribution, metabolism and elimination (ADME) profile. A 100 ns molecular dynamics was performed to analyze the stability of main protease-ligand complex. The RMSD and RMSF value indicate that the protease protein retains approximate stability after binding with the proposed analogue. However, further studies are required to perform   to evaluate the SARS CoV2 main protease inhibitory activity by conducting in-vitro and in-vivo study. In future, the proposed small molecule protease inhibitor analogue can be used for the therapy of COVID-19.

 

Keywords: COVID-19, main protease enzyme(Mpro), Molecular docking, Molecular dynamics

Cite this Article

Arkadeep Sarkar, Arghya Banik, Trambak Basak, Barun Dasgupta. In Silico Identification of Small Molecules as Novel Coronavirus Protease Enzyme Inhibitors. Research & Reviews: A Journal of Bioinformatics. 2020; 7(2): 33–43p.


Downloads

Published

2020-10-01

Issue

Vol. 7 No. 2 (2020)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.